Horizon Pharma Inc. (NASDAQ:HZNP) had its target price hoisted by Mizuho from $29.00 to $30.00 in a research note issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price points to a potential upside of 39.60% from the company’s previous close.
A number of other research analysts have also weighed in on HZNP. Piper Jaffray Cos. reissued an “overweight” rating and set a $33.00 target price (down previously from $34.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Zacks Investment Research raised shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Monday, July 11th. Morgan Stanley set a $24.00 target price on shares of Horizon Pharma and gave the stock a “hold” rating in a research report on Monday, September 12th. Citigroup Inc. boosted their target price on shares of Horizon Pharma from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. Finally, Brean Capital reissued a “buy” rating and set a $30.00 target price on shares of Horizon Pharma in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $29.69.
Shares of Horizon Pharma (NASDAQ:HZNP) traded down 0.97% during trading on Tuesday, reaching $21.49. 630,634 shares of the company’s stock were exchanged. Horizon Pharma has a 52-week low of $13.05 and a 52-week high of $23.44. The company’s market capitalization is $3.47 billion. The company has a 50 day moving average price of $18.68 and a 200-day moving average price of $18.49.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.07. Horizon Pharma had a negative net margin of 1.34% and a positive return on equity of 22.73%. The business earned $273.70 million during the quarter, compared to analyst estimates of $270.04 million. During the same quarter in the previous year, the business earned $0.70 EPS. Horizon Pharma’s quarterly revenue was up 20.8% compared to the same quarter last year. On average, equities analysts forecast that Horizon Pharma will post $2.02 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of HZNP. Quantbot Technologies LP acquired a new stake in Horizon Pharma during the third quarter worth $112,000. Canada Pension Plan Investment Board acquired a new stake in Horizon Pharma during the first quarter worth $114,000. Societe Generale acquired a new stake in Horizon Pharma during the second quarter worth $117,000. SG Americas Securities LLC acquired a new stake in Horizon Pharma during the second quarter worth $117,000. Finally, Nuveen Asset Management LLC acquired a new stake in Horizon Pharma during the second quarter worth $176,000. 87.91% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma Company Profile